Targeting mechanistic target of rapamycin complex 2 attenuates immunopathology in Systemic Lupus Erythematosus

Hu Zeng,Minji Ai,Xian Zhou,Michele Carrer,Paymaan Jafar-nejad,Yanfeng Li,Naomi M. Gades,Mariam P. Alexander,Mario A. Bautista,Ali A. Duarte Garcia

DOI: https://doi.org/10.1101/2024.08.01.606069

2024-08-04

Abstract:Objective: We aim to explore the role of mechanistic target of rapamycin complex (mTORC) 2 in systemic lupus erythematosus (SLE) development, the in vivo regulation of mTORC2 by type I interferon (IFN) signaling in autoimmunity, and to use mTORC2 targeting therapy to ameliorate lupus-like symptoms in an in vivo lupus mouse model and an in vitro coculture model using human PBMCs. Method: We first induced lupus-like disease in T cell specific Rictor, a key component of mTORC2, deficient mice by topical application of imiquimod (IMQ) and monitored disease development. Next, we investigated the changes of mTORC2 signaling and immunological phenotypes in type I IFNAR deficient Lpr mice. We then tested the beneficial effects of anti-Rictor antisense oligonucleotide (Rictor-ASO) in a mouse model of lupus: MRL/lpr mice. Finally, we examined the beneficial effects of RICTOR-ASO on SLE patients' PBMCs using an in vitro T-B cell coculture assay. Results: T cell specific Rictor deficient mice have reduced age-associated B cells, plasma cells and germinal center B cells, and less autoantibody production than WT mice following IMQ treatment. IFNAR1 deficient Lpr mice have reduced mTORC2 activity in CD4+ T cells accompanied by restored CD4+ T cell glucose metabolism, partially recovered T cell trafficking, and reduced systemic inflammation. In vivo Rictor-ASO treatment improves renal function and pathology in MRL/lpr mice, along with improved immunopathology. In human SLE (N = 5) PBMCs derived T-B coculture assay, RICTOR-ASO significantly reduce immunoglobulin and autoantibodies production (P < 0.05). Conclusion: Targeting mTORC2 could be a promising therapeutic for SLE.

Immunology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role of mTORC2 (mechanistic target of rapamycin complex 2) in systemic lupus erythematosus (SLE), and the possibility of alleviating the immunopathological symptoms of SLE by targeting mTORC2. Specifically:

1. **Research Background**:
- SLE is a complex autoimmune disease, characterized by the loss of tolerance to self - antigens and the production of autoantibodies in the body.
- Currently, the treatment of SLE mainly depends on broad - spectrum immunosuppressants, which not only have limited efficacy but may also bring adverse side effects.
- Studies have shown that type I interferon (IFN) signaling pathway plays a crucial role in the pathogenesis of SLE.

2. **Research Objectives**:
- To explore the role of mTORC2 in the development of SLE.
- To study the regulation of mTORC2 by type I IFN signaling pathway in vivo and its impact on autoimmunity.
- To use mTORC2 - targeting therapies (such as the antisense oligonucleotide Rictor - ASO) to improve lupus - like symptoms in SLE mouse models and in vitro human PBMC co - culture models.

3. **Specific Questions**:
- Does mTORC2 play an important role in the T - cell - mediated SLE pathological process?
- How does the type I IFN signaling pathway regulate the activity of mTORC2 and further affect the functions of T - cells and B - cells?
- Can targeting mTORC2 effectively relieve the symptoms of SLE?

Through these studies, the author hopes to provide a theoretical basis for new treatment strategies for SLE, especially whether targeting mTORC2 can become a potential treatment method.